Soleno Therapeutics, Inc. (FRA:6XC)
Germany · Delayed Price · Currency is EUR 41.60
-0.08 (-0.19%)
At close: Nov 28, 2025
Soleno Therapeutics Company Description
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.
The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017.
Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Soleno Therapeutics, Inc.
| Country | United States |
| Founded | 1999 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 92 |
| CEO | Anish Bhatnagar |
Contact Details
Address: 100 Marine Parkway Redwood City, Delaware 94065 United States | |
| Phone | 650 213 8444 |
| Website | soleno.life |
Stock Details
| Ticker Symbol | 6XC |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Anish Bhatnagar | Chief Executive Officer |
| James MacKaness | Chief Financial Officer |
| Anish Bhatnagar | Chief Operating Officer |